Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)

N/A Completed NCT05174312

Summary

The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF). The main objective is to determine if the Reprieve DMS can more efficiently decongest ADHF patients in comparison to Control Therapy.

Total Urine Sodium Output

24 hours post-treatment initiation · mmol of sodium

Clinically Significant Acute Kidney Injury, Severe Electrolyte Abnormality, Symptomatic Hypotension or Hypertensive Emergency.

End of treatment, 0-72 hours. · total number of events

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• Implantation of a Permanent Interatrial Shunt to Reduce Left Atrial Filling Pressures Foll — samir kapadia
• Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant — University of Utah
• Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure — Yale University
• Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using th — Boston Children's Hospital
• PROACTIVE-HF IDE Trial Heart Failure NYHA Class III — Endotronix, Inc.
• Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University

All trials